DOV-216303

DOV 216,303 is a triple reuptake inhibitor that inhibits the reuptake of serotonin, norepinephrine, and dopamine with IC50 values of 14, 20, and 78 nM, respectively. It is an analogue of aminorex and DOV Pharmaceutical is the developer.

Pharmacology

DOV 216,303 is a potent inhibitor of the reuptake of serotonin, norepinephrine, and dopamine. This triple reuptake mechanism may provide a wider therapeutic range than traditional SSRIs or SNRIs. It is structurally related to aminorex, a stimulant drug that was withdrawn from the market due to severe side effects.

Development

DOV 216,303 was developed by DOV Pharmaceutical, a biopharmaceutical company that specializes in the development of novel therapeutics for neurological and psychiatric disorders. The drug was in Phase I clinical trials when DOV Pharmaceutical decided to discontinue its development.

See also

• DOV 102,677
• DOV 21,947
• Aminorex
• Triple reuptake inhibitors

References

DOV-216303 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski